Commentary: Blockade of activin type II receptors with a dual anti-ActRIIA/IIB antibody is critical to promote maximal skeletal muscle hypertrophy

FRONTIERS IN PHARMACOLOGY

dc.creatorDuran, Javier
dc.creatorEstrada-Hormazábal, Manuel Iván
dc.date2021-08-23T22:54:25Z
dc.date2022-07-07T01:35:54Z
dc.date2021-08-23T22:54:25Z
dc.date2022-07-07T01:35:54Z
dc.date2018
dc.date.accessioned2023-08-21T21:32:42Z
dc.date.available2023-08-21T21:32:42Z
dc.identifier1151118
dc.identifier1151118
dc.identifierhttps://hdl.handle.net/10533/251393
dc.identifier.urihttps://repositorioslatinoamericanos.uchile.cl/handle/2250/8284977
dc.descriptionRegular 2015
dc.descriptionFONDECYT
dc.descriptionFONDECYT
dc.languageeng
dc.relationhandle/10533/111557
dc.relationhandle/10533/111541
dc.relationhandle/10533/108045
dc.relationhttps://doi.org/10.3389/fphar.2018.00381
dc.rightsAtribución-NoComercial-SinDerivadas 3.0 Chile
dc.rightshttp://creativecommons.org/licenses/by-nc-nd/3.0/cl/
dc.rightsinfo:eu-repo/semantics/article
dc.rightsinfo:eu-repo/semantics/openAccess
dc.titleCommentary: Blockade of activin type II receptors with a dual anti-ActRIIA/IIB antibody is critical to promote maximal skeletal muscle hypertrophy
dc.titleFRONTIERS IN PHARMACOLOGY
dc.typeArticulo
dc.typeinfo:eu-repo/semantics/publishedVersion


Este ítem pertenece a la siguiente institución